Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark E Dunlap

Showing results (41-50 of 59) with videos related to

Pageof 6
Sort By:
Hypertension (Dallas, Tex. : 1979)|December 12, 2007
Aortic diameter, wall stiffness, and wave reflection in systolic hypertensionGary F Mitchell, Paul R Conlin, Mark E Dunlap, et al.
Proceedings (Baylor University. Medical Center)|April 17, 2024
Early pandemic in-hospital outcomes and mortality risk factors in COVID-19 solid organ transplant patientsLaith Alhuneafat, Muhammad Umar Khalid, Ahmad Jabri, et al.
Journal of Cardiac Failure|December 2, 2008
The heart failure clinic: a consensus statement of the Heart Failure Society of AmericaPaul J Hauptman, Michael W Rich, Paul A Heidenreich, et al.
Journal of the American College of Cardiology|November 27, 2012
6-min walk test provides prognostic utility comparable to cardiopulmonary exercise testing in ambulatory outpatients with systolic heart failureDaniel E Forman, Jerome L Fleg, Dalane W Kitzman, et al.
American Heart Journal|April 29, 2006
Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trialJohn J V McMurray, James B Young, Mark E Dunlap, et al.
Hypertension (Dallas, Tex. : 1979)|April 25, 2007
Long-term trandolapril treatment is associated with reduced aortic stiffness: the prevention of events with angiotensin-converting enzyme inhibition hemodynamic substudyGary F Mitchell, Mark E Dunlap, Wayne Warnica, et al.
Journal of the American College of Cardiology|November 13, 2007
Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM ProgramAkshay S Desai, Karl Swedberg, John J V McMurray, et al.
Circulation. Cardiovascular Quality and Outcomes|August 1, 2013
Global variation in quality of care among patients hospitalized with acute heart failure in an international trial: findings from the acute study clinical effectiveness of nesiritide in decompensated heart failure trial (ASCEND-HF)Jonathan G Howlett, Justin A Ezekowitz, Mohua Podder, et al.
European Journal of Heart Failure|April 27, 2010
Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programmeSu Min Chang, Christopher B Granger, Peter A Johansson, et al.
European Journal of Heart Failure|June 1, 2005
Patient perception of the effect of treatment with candesartan in heart failure. Results of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programmeEileen O'Meara, Eldrin Lewis, Chris Granger, et al.
Pageof 6

Showing results (41-50 of 59) with videos related to

Sort By:
Pageof 6
Hypertension (Dallas, Tex. : 1979)|December 12, 2007
Aortic diameter, wall stiffness, and wave reflection in systolic hypertensionGary F Mitchell, Paul R Conlin, Mark E Dunlap, et al.
Proceedings (Baylor University. Medical Center)|April 17, 2024
Early pandemic in-hospital outcomes and mortality risk factors in COVID-19 solid organ transplant patientsLaith Alhuneafat, Muhammad Umar Khalid, Ahmad Jabri, et al.
Journal of Cardiac Failure|December 2, 2008
The heart failure clinic: a consensus statement of the Heart Failure Society of AmericaPaul J Hauptman, Michael W Rich, Paul A Heidenreich, et al.
Journal of the American College of Cardiology|November 27, 2012
6-min walk test provides prognostic utility comparable to cardiopulmonary exercise testing in ambulatory outpatients with systolic heart failureDaniel E Forman, Jerome L Fleg, Dalane W Kitzman, et al.
American Heart Journal|April 29, 2006
Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trialJohn J V McMurray, James B Young, Mark E Dunlap, et al.
Hypertension (Dallas, Tex. : 1979)|April 25, 2007
Long-term trandolapril treatment is associated with reduced aortic stiffness: the prevention of events with angiotensin-converting enzyme inhibition hemodynamic substudyGary F Mitchell, Mark E Dunlap, Wayne Warnica, et al.
Journal of the American College of Cardiology|November 13, 2007
Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM ProgramAkshay S Desai, Karl Swedberg, John J V McMurray, et al.
Circulation. Cardiovascular Quality and Outcomes|August 1, 2013
Global variation in quality of care among patients hospitalized with acute heart failure in an international trial: findings from the acute study clinical effectiveness of nesiritide in decompensated heart failure trial (ASCEND-HF)Jonathan G Howlett, Justin A Ezekowitz, Mohua Podder, et al.
European Journal of Heart Failure|April 27, 2010
Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programmeSu Min Chang, Christopher B Granger, Peter A Johansson, et al.
European Journal of Heart Failure|June 1, 2005
Patient perception of the effect of treatment with candesartan in heart failure. Results of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programmeEileen O'Meara, Eldrin Lewis, Chris Granger, et al.
Pageof 6